Finance

Lists
Why is NTRA up 2,54%?
Dive Deeper
NTRA:NASDAQ
Natera Inc
400,71 USD
+2,54%
(+9,92) 1D
400,71 USD
0,00% (0,00)
After hours
Closed: 9-окт., 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for NTRA...
Open
392,90 USD
High
407,06 USD
Low
391,51 USD
Mkt. cap
57,76 млд
Avg. vol.
1,64 млн
Volume
1,01 млн
52-wk high
437,41 USD
52-wk low
167,98 USD
EPS
-1,37 USD
Beta
1,50
Shares outstanding
144,14 млн
No. of employees
6 миң
Open
392,90 USD
High
407,06 USD
Low
391,51 USD
Mkt. cap
57,76 млд
Avg. vol.
1,64 млн
Volume
1,01 млн
52-wk high
437,41 USD
52-wk low
167,98 USD
EPS
-1,37 USD
Beta
1,50
Shares outstanding
144,14 млн
No. of employees
6 миң
News stories
From web sources and news partners
Profile
Natera, Inc. is a clinical genetic testing company based in Austin, Texas that specializes in non-invasive, cell-free DNA testing technology, with a focus on women's health, cancer, and organ health. Natera's proprietary technology combines novel molecular biology techniques with a suite of bioinformatics software that allows detection down to a single molecule in a tube of blood. Natera operates CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments in San Carlos, California and Austin, Texas. Wikipedia
About Natera Inc
CEOSteven Chapman
Employees6,14 миң
Founded2004-ж., 1-янв.
HeadquartersОстин, Техас, Америка Кошмо Штаттары
Sector-
Websitenatera.com
Analyst ratings
Based on 20 analysts giving stock ratings to NTRA in the past 3 months
Strong buy
Buy
19
Hold
1
Sell
0
12-month forecast
Based on 20 Wall Street analysts offering 12 month price targets for NTRA in the last 3 months.
Highest
Current 400,71 USD
480,00 USD (+19,79%)
Average
383,24 USD (-4,36%)
Lowest
320,00 USD (-20,14%)
Analyst
Recommendation
Action
Price target
Projected
Date
Luke Sergott
Barclays
Buy
Maintained
475,00 USD
+18,5%
10/07/2026
Patrick B Donnelly
Citi
Buy
Maintained
480,00 USD
+19,8%
10/06/2026
Albert Hu‏
Citi
Buy
Maintained
480,00 USD
+19,8%
10/06/2026
Subbu Nambi
Guggenheim
Buy
Maintained
475,00 USD
+18,5%
10/01/2026
Eve Burstein
Bernstein
Buy
Maintained
365,00 USD
-8,9%
09/25/2026
Dan Leonard
RBC Capital
Buy
Maintained
460,00 USD
+14,8%
09/24/2026
Evie Koslosky
Goldman Sachs
Hold
Maintained
375,00 USD
-6,4%
09/20/2026
Kallum Titchmarsh
Morgan Stanley
Buy
Maintained
355,00 USD
-11,4%
09/14/2026
Unknown Analyst
UBS
Buy
Maintained
435,00 USD
+8,6%
09/09/2026
Doug Schenkel
UBS
Buy
Maintained
435,00 USD
+8,6%
09/09/2026
Jamie Clark
Rothschild & Co Redburn
Buy
Initiated
385,00 USD
-3,9%
09/08/2026
David Westenberg
Piper Sandler
Buy
Maintained
363,50 USD
-9,3%
08/24/2026
Tycho Peterson
Jefferies
Buy
Maintained
330,00 USD
-17,6%
08/17/2026
‏Brendan Digan‏
Citi
Buy
Maintained
365,00 USD
-8,9%
08/14/2026
Unknown Analyst
Stephens
Buy
Maintained
350,00 USD
-12,7%
08/12/2026
Matt Larew
William Blair
Buy
Reiterated
-
-
08/07/2026
Daniel Markowitz CFA
Evercore ISI
Buy
Maintained
360,00 USD
-10,2%
08/07/2026
Catherine Ramsey Schulte
Robert W. Baird
Buy
Maintained
348,00 USD
-13,2%
08/07/2026
Kyle Mikson CFA
Canaccord Genuity
Buy
Maintained
375,00 USD
-6,4%
08/07/2026
Brandon Couillard
Wells Fargo
Hold
Maintained
284,00 USD
-29,1%
08/07/2026
Casey Woodring
J.P. Morgan
Buy
Reiterated
360,00 USD
-10,2%
08/07/2026
Mark Massaro
BTIG
Buy
Reiterated
320,00 USD
-20,1%
08/07/2026
Puneet Souda
Leerink Partners
Buy
Maintained
330,00 USD
-17,6%
08/07/2026
Daniel Brennan
TD Cowen
Buy
Reiterated
340,00 USD
-15,2%
08/07/2026
William Bonello
Craig-Hallum
Buy
Maintained
-
-
07/09/2026
Paige Chamberlain‏
Wolfe Research
Buy
Reiterated
260,00 USD
-35,1%
06/01/2026
Unknown Analyst
Wolfe Research
Buy
Reiterated
260,00 USD
-35,1%
06/01/2026
Andrew Brackmann
William Blair
Buy
Maintained
-
-
05/08/2026
Unknown Analyst
Jefferies
Buy
Reiterated
275,00 USD
-31,4%
02/27/2026
Last report
2026-ж., 6-авг.
Fiscal period
Q2 2026
-0,47 USD / -0,53 USD
+11,99%beat
Revenue / Est. (USD)
752,75 млн / 661,29 млн
+13,83%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
592,18 млн
665,50 млн
696,64 млн
752,75 млн
Cost of goods sold
207,80 млн
220,07 млн
245,81 млн
267,56 млн
Cost of revenue
207,80 млн
220,07 млн
245,81 млн
267,56 млн
Research and development expenses
173,41 млн
175,19 млн
210,70 млн
228,07 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
308,55 млн
291,30 млн
320,74 млн
328,87 млн
Operating expense
481,96 млн
468,21 млн
537,15 млн
562,65 млн
Total operating expenses
689,76 млн
688,28 млн
782,96 млн
830,21 млн
Operating income
-97,58 млн
-22,78 млн
-86,32 млн
-77,46 млн
Other non operating income
-
-
-
-
EBT including unusual items
-87,34 млн
-13,33 млн
-84,81 млн
-67,23 млн
EBT excluding unusual items
-87,34 млн
-13,33 млн
-77,61 млн
-68,90 млн
Income tax expense
207,00 миң
-60,58 млн
283,00 миң
-261,00 миң
Effective tax rate
-0,24%
454,63%
-0,33%
0,39%
Other operating expenses
-
-
-
-
Net income
-87,54 млн
47,26 млн
-85,09 млн
-66,97 млн
Net profit margin
-14,78%
7,10%
-12,21%
-8,90%
Earnings per share
-0,64
0,36
-0,60
-0,47
Interest and investment income
11,28 млн
10,45 млн
9,60 млн
9,45 млн
Interest expense
-1,04 млн
-991,00 миң
-892,00 миң
-890,00 миң
Net interest expenses
10,24 млн
9,46 млн
8,71 млн
8,56 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-87,28 млн
-13,69 млн
-66,09 млн
-56,27 млн
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google колдонмолору